BioLife Solutions, Inc. (NASDAQ:BLFS - Get Free Report) EVP Aby J. Mathew sold 547 shares of the stock in a transaction dated Wednesday, October 30th. The stock was sold at an average price of $23.15, for a total value of $12,663.05. Following the transaction, the executive vice president now directly owns 317,169 shares in the company, valued at approximately $7,342,462.35. The trade was a 0.00 % decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through this hyperlink.
BioLife Solutions Stock Up 2.9 %
NASDAQ BLFS traded up $0.67 on Friday, hitting $24.07. 216,495 shares of the stock were exchanged, compared to its average volume of 367,540. BioLife Solutions, Inc. has a fifty-two week low of $9.92 and a fifty-two week high of $26.73. The company has a 50-day moving average price of $24.04 and a 200-day moving average price of $22.16. The company has a quick ratio of 1.81, a current ratio of 2.86 and a debt-to-equity ratio of 0.04. The company has a market cap of $1.11 billion, a PE ratio of -14.24 and a beta of 1.88.
BioLife Solutions (NASDAQ:BLFS - Get Free Report) last issued its earnings results on Thursday, August 8th. The medical equipment provider reported ($0.06) EPS for the quarter, topping analysts' consensus estimates of ($0.14) by $0.08. The firm had revenue of $28.33 million during the quarter, compared to the consensus estimate of $23.80 million. BioLife Solutions had a negative net margin of 59.88% and a negative return on equity of 10.75%. Sell-side analysts anticipate that BioLife Solutions, Inc. will post -0.36 EPS for the current fiscal year.
Wall Street Analyst Weigh In
Several analysts have recently issued reports on BLFS shares. Craig Hallum increased their price target on shares of BioLife Solutions from $23.00 to $30.00 and gave the stock a "buy" rating in a research report on Monday, August 12th. Northland Securities upped their target price on shares of BioLife Solutions from $26.00 to $28.00 and gave the stock an "outperform" rating in a research note on Friday, August 9th. HC Wainwright assumed coverage on shares of BioLife Solutions in a research report on Monday, September 30th. They issued a "buy" rating and a $29.00 price target for the company. Finally, TD Cowen upped their price objective on BioLife Solutions from $20.00 to $26.00 and gave the stock a "buy" rating in a research report on Wednesday, July 17th. One analyst has rated the stock with a sell rating and six have issued a buy rating to the company. According to MarketBeat.com, the company currently has an average rating of "Moderate Buy" and an average price target of $26.67.
Get Our Latest Report on BioLife Solutions
Institutional Inflows and Outflows
A number of hedge funds have recently made changes to their positions in BLFS. BNP Paribas Financial Markets grew its position in shares of BioLife Solutions by 249.5% in the 1st quarter. BNP Paribas Financial Markets now owns 53,515 shares of the medical equipment provider's stock valued at $993,000 after buying an additional 38,201 shares during the last quarter. Sequoia Financial Advisors LLC purchased a new position in shares of BioLife Solutions during the second quarter worth about $466,000. Vanguard Group Inc. increased its position in shares of BioLife Solutions by 11.5% during the first quarter. Vanguard Group Inc. now owns 2,868,335 shares of the medical equipment provider's stock worth $53,208,000 after purchasing an additional 296,727 shares in the last quarter. Isthmus Partners LLC lifted its holdings in shares of BioLife Solutions by 34.4% in the 2nd quarter. Isthmus Partners LLC now owns 165,247 shares of the medical equipment provider's stock valued at $35,000 after purchasing an additional 42,265 shares during the last quarter. Finally, Mutual of America Capital Management LLC acquired a new stake in shares of BioLife Solutions in the 2nd quarter valued at about $8,592,000. Hedge funds and other institutional investors own 93.24% of the company's stock.
BioLife Solutions Company Profile
(
Get Free Report)
BioLife Solutions, Inc develops, manufactures, and markets bioproduction tools and services for the cell and gene therapy (CGT) industry in the United States, Europe, the Middle East, Africa, and internationally. The company's products are used in the basic and applied research, and commercial manufacturing of biologic-based therapies.
Recommended Stories
Before you consider BioLife Solutions, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and BioLife Solutions wasn't on the list.
While BioLife Solutions currently has a "Buy" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking to avoid the hassle of mudslinging, volatility, and uncertainty? You'd need to be out of the market, which isn’t viable. So where should investors put their money? Find out with this report.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
